Adenosine A2A receptor activation promotes wound neovascularization by stimulating angiogenesis and vasculogenesis

M. Carmen Montesinos, Jason P. Shaw, Herman Yee, Peter Shamamian, Bruce N. Cronstein

Research output: Contribution to journalArticle

101 Citations (Scopus)

Abstract

Recent reports indicate that circulating endothelial progenitor cells (EPCs) may be recruited to sites of neovascularization where they differentiate into endothelial cells (EC). As we have previously demonstrated that adenosine A2A agonists promote neovascularization in wounds, we sought to determine whether adenosine A2A receptor agonist-augmented wound healing involves vessel sprouting (angiogenesis) or EPC recruitment (vasculogenesis) or both. Four weeks after bone marrow reconstitution from donor FVB/N Tie2GFP transgenic mice, two full-thickness excisional wounds were performed on the dorsum of FVB/N wild-type mice and treated with either an A2A receptor agonist (CGS-21680) or vehicle alone. Vessel density, as measured by CD31 staining, and density of EPC-derived vessels, as measured by GFP expression, were quantified in a blinded fashion using two-color fluorescence microscopy. We observed nearly a three-fold increase in CD31-positive vessels and a more than 10-fold increase in GFP-positive cells in A2A agonist-treated 3-day old wounds, but by 6 days after wounding the differences between A2A agonist-treated and vehicle-treated wounds were no longer statistically significant. In conclusion, this is the first evidence that an exogenous agent such as an adenosine A2A receptor agonist increases neovascularization in the early stages of wound repair by increasing both EPC recruitment (vasculogenesis) and local vessel sprouting (angiogenesis).

Original languageEnglish (US)
Pages (from-to)1887-1892
Number of pages6
JournalAmerican Journal of Pathology
Volume164
Issue number6
StatePublished - Jun 2004
Externally publishedYes

Fingerprint

Adenosine A2A Receptors
Adenosine A2 Receptor Agonists
Wounds and Injuries
Fluorescence Microscopy
Adenosine
Wound Healing
Transgenic Mice
Endothelial Cells
Color
Bone Marrow
Staining and Labeling
Endothelial Progenitor Cells

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Adenosine A2A receptor activation promotes wound neovascularization by stimulating angiogenesis and vasculogenesis. / Montesinos, M. Carmen; Shaw, Jason P.; Yee, Herman; Shamamian, Peter; Cronstein, Bruce N.

In: American Journal of Pathology, Vol. 164, No. 6, 06.2004, p. 1887-1892.

Research output: Contribution to journalArticle

Montesinos, M. Carmen ; Shaw, Jason P. ; Yee, Herman ; Shamamian, Peter ; Cronstein, Bruce N. / Adenosine A2A receptor activation promotes wound neovascularization by stimulating angiogenesis and vasculogenesis. In: American Journal of Pathology. 2004 ; Vol. 164, No. 6. pp. 1887-1892.
@article{b2f24483d4cc4e2aba0016a3062199c8,
title = "Adenosine A2A receptor activation promotes wound neovascularization by stimulating angiogenesis and vasculogenesis",
abstract = "Recent reports indicate that circulating endothelial progenitor cells (EPCs) may be recruited to sites of neovascularization where they differentiate into endothelial cells (EC). As we have previously demonstrated that adenosine A2A agonists promote neovascularization in wounds, we sought to determine whether adenosine A2A receptor agonist-augmented wound healing involves vessel sprouting (angiogenesis) or EPC recruitment (vasculogenesis) or both. Four weeks after bone marrow reconstitution from donor FVB/N Tie2GFP transgenic mice, two full-thickness excisional wounds were performed on the dorsum of FVB/N wild-type mice and treated with either an A2A receptor agonist (CGS-21680) or vehicle alone. Vessel density, as measured by CD31 staining, and density of EPC-derived vessels, as measured by GFP expression, were quantified in a blinded fashion using two-color fluorescence microscopy. We observed nearly a three-fold increase in CD31-positive vessels and a more than 10-fold increase in GFP-positive cells in A2A agonist-treated 3-day old wounds, but by 6 days after wounding the differences between A2A agonist-treated and vehicle-treated wounds were no longer statistically significant. In conclusion, this is the first evidence that an exogenous agent such as an adenosine A2A receptor agonist increases neovascularization in the early stages of wound repair by increasing both EPC recruitment (vasculogenesis) and local vessel sprouting (angiogenesis).",
author = "Montesinos, {M. Carmen} and Shaw, {Jason P.} and Herman Yee and Peter Shamamian and Cronstein, {Bruce N.}",
year = "2004",
month = "6",
language = "English (US)",
volume = "164",
pages = "1887--1892",
journal = "American Journal of Pathology",
issn = "0002-9440",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Adenosine A2A receptor activation promotes wound neovascularization by stimulating angiogenesis and vasculogenesis

AU - Montesinos, M. Carmen

AU - Shaw, Jason P.

AU - Yee, Herman

AU - Shamamian, Peter

AU - Cronstein, Bruce N.

PY - 2004/6

Y1 - 2004/6

N2 - Recent reports indicate that circulating endothelial progenitor cells (EPCs) may be recruited to sites of neovascularization where they differentiate into endothelial cells (EC). As we have previously demonstrated that adenosine A2A agonists promote neovascularization in wounds, we sought to determine whether adenosine A2A receptor agonist-augmented wound healing involves vessel sprouting (angiogenesis) or EPC recruitment (vasculogenesis) or both. Four weeks after bone marrow reconstitution from donor FVB/N Tie2GFP transgenic mice, two full-thickness excisional wounds were performed on the dorsum of FVB/N wild-type mice and treated with either an A2A receptor agonist (CGS-21680) or vehicle alone. Vessel density, as measured by CD31 staining, and density of EPC-derived vessels, as measured by GFP expression, were quantified in a blinded fashion using two-color fluorescence microscopy. We observed nearly a three-fold increase in CD31-positive vessels and a more than 10-fold increase in GFP-positive cells in A2A agonist-treated 3-day old wounds, but by 6 days after wounding the differences between A2A agonist-treated and vehicle-treated wounds were no longer statistically significant. In conclusion, this is the first evidence that an exogenous agent such as an adenosine A2A receptor agonist increases neovascularization in the early stages of wound repair by increasing both EPC recruitment (vasculogenesis) and local vessel sprouting (angiogenesis).

AB - Recent reports indicate that circulating endothelial progenitor cells (EPCs) may be recruited to sites of neovascularization where they differentiate into endothelial cells (EC). As we have previously demonstrated that adenosine A2A agonists promote neovascularization in wounds, we sought to determine whether adenosine A2A receptor agonist-augmented wound healing involves vessel sprouting (angiogenesis) or EPC recruitment (vasculogenesis) or both. Four weeks after bone marrow reconstitution from donor FVB/N Tie2GFP transgenic mice, two full-thickness excisional wounds were performed on the dorsum of FVB/N wild-type mice and treated with either an A2A receptor agonist (CGS-21680) or vehicle alone. Vessel density, as measured by CD31 staining, and density of EPC-derived vessels, as measured by GFP expression, were quantified in a blinded fashion using two-color fluorescence microscopy. We observed nearly a three-fold increase in CD31-positive vessels and a more than 10-fold increase in GFP-positive cells in A2A agonist-treated 3-day old wounds, but by 6 days after wounding the differences between A2A agonist-treated and vehicle-treated wounds were no longer statistically significant. In conclusion, this is the first evidence that an exogenous agent such as an adenosine A2A receptor agonist increases neovascularization in the early stages of wound repair by increasing both EPC recruitment (vasculogenesis) and local vessel sprouting (angiogenesis).

UR - http://www.scopus.com/inward/record.url?scp=2442689337&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2442689337&partnerID=8YFLogxK

M3 - Article

VL - 164

SP - 1887

EP - 1892

JO - American Journal of Pathology

JF - American Journal of Pathology

SN - 0002-9440

IS - 6

ER -